Sugi Predict

Sugi Predict / Targets / CYP2E1

CYP2E1

Cytochrome P450 2E1 · P05181 · CYP2E1 on Sugi Atlas →

34,255 patent compounds predicted against CYP2E1, 20,153 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL210356 SCHEMBL210356 0.74 9/20
SCHEMBL434197 SCHEMBL434197 0.63 8/20
SCHEMBL211177 SCHEMBL211177 0.57 7/20
SCHEMBL156922 SCHEMBL156922 0.51 7/20
SCHEMBL216242 SCHEMBL216242 0.56 6/20
SCHEMBL364159 SCHEMBL364159 0.53 6/20
SCHEMBL289944 SCHEMBL289944 0.53 6/20
SCHEMBL364613 SCHEMBL364613 0.51 6/20
SCHEMBL209292 SCHEMBL209292 0.51 6/20
SCHEMBL364612 SCHEMBL364612 0.55 4/20
SCHEMBL324539 SCHEMBL324539 0.54 4/20
SCHEMBL334755 SCHEMBL334755 0.46 4/20
SCHEMBL152405 SCHEMBL152405 0.45 4/20
SCHEMBL158705 SCHEMBL158705 1.00 3/20
SCHEMBL291163 SCHEMBL291163 0.61 3/20
SCHEMBL120088 SCHEMBL120088 0.58 3/20
SCHEMBL2386 SCHEMBL2386 0.57 3/20
SCHEMBL210572 SCHEMBL210572 0.56 3/20
SCHEMBL252650 SCHEMBL252650 0.55 3/20
SCHEMBL290740 SCHEMBL290740 0.53 3/20

Clinical trials — most relevant to CYP2E1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing PHASE4COMPLETED
APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors PHASE4WITHDRAWN
Role of Antioxidants Supplementation in Chronic Pancreatitis PHASE3COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer PHASE1/PHASE2COMPLETED
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). PHASE2UNKNOWN
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib PHASE2RECRUITING
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis PHASE2COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer PHASE1COMPLETED
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab PHASE1COMPLETED
Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone PHASE1UNKNOWN
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects PHASE1NOT_YET_RECRUITING
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab PHASE1COMPLETED
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) PHASE1COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies PHASE1UNKNOWN
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants PHASE1COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease PHASE1COMPLETED
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions PHASE1COMPLETED
AZD1981 Midazolam CYP4503A Induction Study PHASE1COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer nanCOMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics nanCOMPLETED
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients nanCOMPLETED
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy nanUNKNOWN
Pharmacokinetics and Pharmacodynamics of Intravenous Paracetamol in Morbidly Obese and Non- Obese Patients. nanRECRUITING
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk nanCOMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia nanNOT_YET_RECRUITING
The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis nanUNKNOWN
APAP Hepatotoxicity After Therapeutic Doses nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP2E1 binder may also engage these)

ProteinNameSimilarity
Q6GUQ4 — 1.000 Q6GUQ4 →
O18963 — 0.999 O18963 →
P79383 — 0.998 P79383 →
P08682 — 0.997 P08682 →
P51581 — 0.997 P51581 →
Q9MZY0 — 0.996 Q9MZY0 →
Q05421 — 0.995 Q05421 →
P11510 — 0.994 P11510 →
Q91W64 — 0.994 Q91W64 →
P19225 — 0.994 P19225 →
CYP2J2 Cytochrome P450 2J2 0.994 landscape →
P11711 — 0.994 P11711 →
O54749 — 0.993 O54749 →
E9Q5K4 — 0.993 E9Q5K4 →
P33264 — 0.992 P33264 →
P13107 — 0.992 P13107 →
P00181 — 0.992 P00181 →
P33266 — 0.992 P33266 →
P24455 — 0.992 P24455 →
P56593 — 0.992 P56593 →
Q29510 — 0.992 Q29510 →
P33273 — 0.992 P33273 →
P20814 — 0.991 P20814 →
P05179 — 0.991 P05179 →
P33265 — 0.991 P33265 →
P56657 — 0.991 P56657 →
O62671 — 0.991 O62671 →
P05182 — 0.990 P05182 →
P33272 — 0.990 P33272 →
P56654 — 0.990 P56654 →